|
|
Post by fofos2000i on Jan 13, 2016 6:06:16 GMT -5
hope they kept minutes at the JAC (Joint Afrezza Committee) meetings ; what Sanofi said and did
|
|
|
|
Post by slugworth008 on Jan 13, 2016 6:52:13 GMT -5
Im not surprised at all. Sanofi should be sued. I couldn't agree more. The evidence is piling up. Al needs to pull the trigger - It would send a message that deserves to be sent. |
|
|
|
Post by slugworth008 on Jan 13, 2016 6:53:43 GMT -5
With more and more comments like this, it looks more and more likely that Sanofi may offer to pay a parting settlement to Mannkind to save its reputation. Pfizer gave Nektar $130 million as a parting settlement for such purpose within one month after it announced dropping Exubera. At this point of time, a $50-100 million parting settlement would help Mannkind's balance sheet greatly. I'm surprised that a termination clause with a monetary amount wasn't part of the partnership agreement. |
|
|
|
Post by slugworth008 on Jan 13, 2016 6:56:03 GMT -5
From YMB to apply grain of salt. regenmedprovider • 13 minutes ago Flag 10users liked this postsusers disliked this posts0Reply Talked to my SNY reps today Who were well aware of the split. They said SNY only rolled it out to targeted Endo's who were extremely pleased with the results with Afrezza. Patients love it, Endo's LOVE it. But the Endo's don't do Pulmonary Function tests in their offices and had to send the patients out to either a primary care provider or to pulmonologists. So it was cumbersome. SNY didn't open up Afrezza to their wider sales force and when I asked why only the Endo's and not primary care providers I got the big "We don't know?" I told them we in primary care do PFT's routinely and many of us were curious as to why we weren't also targeted the answer was another "I don't know because everyone knows primary care providers see patients more frequently and know them better." We manage their care routinely. Here's my advice to the next marketer: target the Certified Diabetic Educators, Primacy Care MDs, NPs and PAs. Offer to provide a free PFT machine if they don't already have one. It is relatively inexpensive and they can be reimbursed by Medicare and 3rd Party Payors. Because SNY, although they know Afrezza was an outstanding product, for some reason, chose the most cumbersome and difficult to reach target market, Endo's. I predict more on this will come out, and that the next partner will be much more broad in its marketing scope. Less are you guys kidding me. The credible ymb poster... Hahaha pathetic!! I've followed regenmedproviders posts for quite some time. Personally I think they are accurate. You have your opinion - I have mine. |
|
|
|
Post by mnholdem on Jan 13, 2016 8:39:21 GMT -5
With more and more comments like this, it looks more and more likely that Sanofi may offer to pay a parting settlement to Mannkind to save its reputation. Pfizer gave Nektar $130 million as a parting settlement for such purpose within one month after it announced dropping Exubera. At this point of time, a $50-100 million parting settlement would help Mannkind's balance sheet greatly. I'm surprised that a termination clause with a monetary amount wasn't part of the partnership agreement. Perhaps the fact that Sanofi paid for 65% of all development/commercialization expense was considered sufficient should the agreement be terminated. MannKind would have to convince Sanofi that they plan to give them a big black eye in public for Sanofi to pony up an unplanned divorce settlement. |
|
|
|
Post by kc on Jan 13, 2016 8:43:30 GMT -5
hope they kept minutes at the JAC (Joint Afrezza Committee) meetings ; what Sanofi said and did You can bet they both kept great minutes. First get you market plan together. Worry about suits down they road. There is a long statute of limitation on taking action . |
|
|
|
Post by kc on Jan 13, 2016 8:45:17 GMT -5
With more and more comments like this, it looks more and more likely that Sanofi may offer to pay a parting settlement to Mannkind to save its reputation. Pfizer gave Nektar $130 million as a parting settlement for such purpose within one month after it announced dropping Exubera. At this point of time, a $50-100 million parting settlement would help Mannkind's balance sheet greatly. I'm surprised that a termination clause with a monetary amount wasn't part of the partnership agreement. That is probably what is in the redacted CTO pages. |
|
|
|
Post by dstevenson on Jan 13, 2016 8:53:24 GMT -5
Sanofi will need to pay 200m+ imo
|
|
